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ABSTRACT [Max words: 250; Currently: 250] 
Background: Glaucoma services are under unprecedented pressure. The UK Healthcare Safety 
Investigation Branch recently called for new ways to identify glaucoma patients most at risk of 
developing sight loss, and of filtering-out false-positive referrals. Here we evaluate the feasibility of 
one such technology, “Eyecatcher”: a free, tablet-based ‘triage’ perimeter, designed to be used 
unsupervised directly within clinic waiting areas. It does not require a button or headrest: patients are 
simply required to look at fixed-luminance dots as they appear. 
Methods: Seventy-seven people were tested twice using Eyecatcher (one eye only) while waiting for a 
routine appointment in a UK glaucoma clinic. The sample included individuals with an established 
diagnosis of glaucoma, and false-positive new referrals (no visual field or optic nerve abnormalities). 
No attempts were made to control the testing environment. Patients wore their own glasses and 
received minimal task instructions. 
Results: Eyecatcher was fast (median: 2.5 mins), produced results in good agreement with standard 
automated perimetry (SAP), and was rated as more enjoyable, less tiring, and easier to perform than 
SAP (P<0.001). It exhibited good separation (ROC=0.97) between eyes with advanced field loss (Mean 
Deviation <-6 dB) and those within normal limits (MD > -2 dB). And it was able to flag two thirds of 
false-positive referrals as functionally normal. However, eight people (10%) failed to complete the test 
twice, and reasons for this limitation are also discussed. 
Conclusions: Tablet-based eye-movement perimetry could potentially provide a pragmatic way of 
triaging busy glaucoma clinics (flagging high-risk patients and possible false-referrals). 
KEY WORDS: glaucoma; visual fields; static perimetry; eye-movements; triage  
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1. INTRODUCTION 1 
British glaucoma services are under strain from an ageing population and more cautious referral 2 
policies1. There is an increasing backlog of appointments2, and it is believed that around twenty 3 
patients a month suffer severe avoidable sight loss as a result of appointment delays3.  A recent report 4 
by the UK Healthcare Safety Investigation Branch (HSIB) found that the lack of timely monitoring is 5 
putting patient safety at risk and recommended “better, smarter ways of working … to maximise the 6 
current capacity” 4. The HSIB report highlighted, in particular, the need to develop new ways to: (1)  7 
identify and prioritise patients most at risk of developing sight loss, and (2) filter-out false-positive 8 
referrals (~40% of new referrals, in the UK5,6 and mainland Europe7,8). 9 
The great majority of patients likely to experience statutory blindness within their lifetime, already 10 
have marked visual field [VF] loss at first presentation to a glaucoma clinic9 (i.e., a Mean Deviation 11 
[MD] worse than −6 dB in at least one eye). A healthy VF is also a key indicator that a patient has been 12 
referred in error. A simple VF assessment --- conducted immediately as the patient enters the clinic, or 13 
as they sit in the waiting room --- could therefore be one possible step towards achieving HSIB’s goals 14 
of prioritising high-risk patients and flagging-up likely false-positive referrals. 15 
Standard automated perimetry [SAP] is inappropriate for this ‘rapid triage’ role, as it requires 16 
specialist equipment and a trained technician. Thus, it is not unknown for patients to wait several 17 
hours for an SAP exam: a potential bottle-beck in patient flow in itself. Our vision is therefore not to 18 
replace SAP, but to complement it with a simpler ‘triage’ assessment, that is inexpensive, and could 19 
be used directly in glaucoma waiting rooms. 20 
A VF triage assessment would not be a like-for-like replacement for SAP. The examination might be 21 
simpler and less detailed: with fewer test locations, and/or fixed-luminance stimuli. Instead, it should 22 
focus on identifying individuals with no measurable visual field loss, and highlighting those individuals 23 
most at risk of developing sight loss within their lifetime (e.g., younger adults with worse than MD -6 24 
dB loss in one eye9). Crucially, however, a triage exam must not add to the existing burden faced by 25 
patients and clinicians. In practical terms, this means a test that --- unlike SAP10 --- is extremely easy to 26 
administer, does not require bulky or expensive equipment, and does not require a trained operator 27 
or dedicated space in which to run. 28 
We recently proposed one such test11: Eyecatcher, an open-source eye-movement perimeter that 29 
combines the portability of an inexpensive tablet computer12–18, with the ease and comfort afforded 30 
Eyecatcher: An open-source tablet perimeter      Page 4 of 13 
by modern eye- and head-tracking technologies19–23. In brief, the patient sits in front of an ordinary 31 
tablet screen, and is simply asked to look at anything they see appear (a largely reflexive response, 32 
present from birth24). Unlike traditional SAP, there is no response button or central fixation target. 33 
Instead, the eye-tracker determines where on the screen to present a given stimulus in order to 34 
stimulate a particular retinal location (i.e., relative to the current point of fixation). The eye-tracker 35 
then analyses eye-movements to determine whether the user saw the stimulus. The use of head-36 
tracking also removes the need for head restraints, since the size and location of the stimulus is scaled 37 
dynamically to compensate for viewing distance. In short, Eyecatcher removes headrests, fixation 38 
spots and response buttons from perimetry, and as a result delivers a more portable, intuitive, and 39 
comfortable test, and one which can be run autonomously, since, unlike SAP, it does not require an 40 
operator to explain the test or monitor fixation. 41 
We have shown previously that Eyecatcher provides VF data concordant with SAP when applied to a 42 
small, self-selecting sample of research participants12. Here we examined the feasibility of applying it 43 
in a busy glaucoma clinic; and in particular, whether it can be used as a rapid triage test to identify 44 
high-risk individuals (MD < -6 dB), and false-positive referrals (no visual field or optic nerve 45 
abnormalities).  46 
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2. METHODS 47 
2.1. Participants 48 
Participants were 77 adults, sampled opportunistically from individuals attending routine 49 
appointments at the glaucoma clinic of Royal Surrey County Hospital: A secondary care centre in 50 
south-east England. No attempt was made to select participants, and the only inclusion requirement 51 
was the capacity to provide written informed consent. The cohort included both returning patients 52 
with an established diagnosis, and 11 new referrals (Table I). This study was approved by the NHS 53 
Health Research Authority (IRAS ID: #230440) and was conducted in accordance with the Declaration 54 
of Helsinki. 55 
2.2. Eyecatcher 56 
The version of Eyecatcher (v2.0) used in the present study is an updated version of that described 57 
previously12. In brief, participants sat approximately 55 cm in front of a Windows Surface Pro 4 tablet 58 
computer (Microsoft, Redmond, Washington, U.S.), and were asked simply to “look at anything you 59 
see” (Figure 1A). On each trial, an inexpensive (~£100) clip-on eye-tracker (Tobii EyeX; Tobii 60 
Technology, Stockholm, Sweden) was used to position fixed-luminance stimuli relative to the current 61 
estimated point of fixation (no central fixation marker), and to determine whether the participant 62 
looked towards the target (no response button; Figure 1D). Viewing distance was not strictly 63 
controlled, but was monitored in real-time by the eye-tracker, and was used to scale the size and 64 
location of the stimulus as required, prior to each presentation. Patients were not supervised during 65 
testing, although the experimenter typically remained nearby (performing paperwork). 66 
Stimuli were Goldmann III targets, 6 dB more intense than the expected threshold of normal adult at 67 
each grid location25 (NB: this value was not adjusted for patient age, but could be in future). The -6 dB 68 
cutoff was chosen since 90% of patients at risk of statutory blindness within their lifetime have an MD 69 
worse than −6 dB at presentation9. For other clinical applications (e.g., case-finding or home 70 
monitoring) a different cutoff may be more appropriate. Additional technical details are given in 71 
Supplemental Text. The complete source code for Eyecatcher is available online at 72 
https://github.com/petejonze/Eyecatcher, and is free for non-commercial use. 73 
The output from Eyecatcher is a retinotopic map, giving the probability of seeing the target at 22 74 
paracentral locations (Figure 1B), including 11 of the most informative points from the 24-2 grid, as 75 
identified by Wang & Henson (2013)26. These 22 values were interpolated to provide a continuous 76 
probability map (Figure 1C), ranging from bright green (‘always seen’) to bright red (‘never seen’, VF 77 
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loss). A summary measure was computed by mean-averaging the probability-of-seeing values across 78 
the 22 locations. The resultant metric, “Mean Hit Rate”, is a number between 0 and 1 that reflects the 79 
amount of ‘greenness’ in the VF plot. It is potentially comparable to the HFA’s summary measure of VF 80 
loss: mean deviation (MD). 81 
[ Figure 1 About Here ] 82 
Figure 1. Eyecatcher. (A) Apparatus and stimuli. The tablet screen measured 26cm x 17.3cm (26.6° x 17.9° when viewed at 83 
55 cm). The eye-tracker is magnetically attached to the base of the tablet. (B) Test Grid, in degrees visual angle (C) Example 84 
Output. Green areas indicated hits (target looked at). Red areas indicate misses (target not looked at). (D) Example test 85 
sequence. On each trial a single fixed-intensity light spot was presented, and the computer determines whether or not an 86 
eye-movement was made towards it. Note that stimuli were presented relative to the current point of fixation, and so 87 
could appear at any screen location throughout the course of the test. See Supplemental Video S1 for example test 88 
sequence. 89 
2.3. Procedure 90 
In each participant, only a single eye was tested. The test eye was randomly selected, and the fellow 91 
eye patched with a cotton swab (monocular viewing). Testing was performed twice consecutively 92 
(same eye), to assess test-retest repeatability. To reflect the fact that Eyecatcher is intended as a rapid 93 
and easy-to-administer assay, no refractive correction was provided. However, patients were asked to 94 
wear their own near-vision spectacles if available.  95 
Testing took place in whichever space was available that would not disturb other patients (typically an 96 
office or consulting room adjacent to the main clinic waiting area). Lights were dimmed where 97 
possible, but no attempt was made to maintain a precise light level. No attempt was made to prevent 98 
patients or members of staff walking past during testing, and this occurred regularly. 99 
Following the test, participants were given a short usability questionnaire, containing five Likert 100 
statements (e.g., “I found the test easy to perform”). Participants answered each question twice: once 101 
for Eyecatcher, and once for SAP. 102 
All testing took part in a single session: generally while the patient waited for SAP or their subsequent 103 
consultation. A minority of individuals had received a mydriatic (tropicamide) by the time they 104 
performed Eyecatcher. However, this was not systematically recorded. 105 
As part of their scheduled appointment, all participants underwent a full visual assessment by the 106 
local clinical team, including a monocular SAP assessment (24-2; SITA Fast) using the Humphrey Field 107 
Analyzer (Carl Zeiss Meditec, CA, USA). 108 
2.4. Analysis 109 
Data are described using non-parametric statistics (e.g., medians), with 95% confidence intervals 110 
computed using bootstrapping (N = 20,000; bias-corrected and accelerated method).   111 
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3. RESULTS   112 
Seventy-seven participants (33 female) were recruited, including 11 new referrals (see Table 1 for 113 
breakdown). All 11 new referrals were judged by their treating physician to be false-positive referrals, 114 
with no visual field or optic nerve abnormalities. No individuals were excluded from the study, and 115 
only one additional individual was approached, but declined to participate in the study. We were 116 
therefore able to obtain a relatively representative sample of ‘typical’ clinic attendees. Median (IQR) 117 




all new referrals only 
Primary Open Angle Glaucoma 44 0 
Normal Tension Glaucoma 5 0 
Primary Angle Closure (PAC) 2 0 
PAC w/ Glaucoma 2 0 
Ocular Hypertension (OHT) 7 1 
OHT w/ borderline Glaucoma 3 0 
Pigmentary Glaucoma 1 0 
Other (complex cases) 3 0 
Nil abnormal 10 10 
Total (all participants) 77 11 
Table 1. Breakdown of diagnoses for the full cohort (N=77, including new referrals), and for the subset of individuals who 119 
were new referrals to the clinic (N=11). 120 
3.1. Completion Rate 121 
Sixty-nine patients (90%) completed Eyecatcher twice without difficulty, but 8 did not. One early 122 
failure was due to a technical error. The remaining 7 failures were due to the eye-tracking hardware 123 
being unable to track the eye reliably (returning no data, or data that was sporadic and imprecise). 124 
The cause of these eye-tracking failures could not be conclusively established. However, of these 125 
seven cases: five may have been due to recent ophthalmic interventions (four had recently undergone 126 
cataract surgery, one had complex pathology due to radiotherapy for cavernous meningioma). One 127 
was believed due to dry eyes (a symptom of an oral steroid, taken for a non-ophthalmic condition). 128 
One eye could not be tracked for reasons unknown: the only distinctive feature was pupil dilation with 129 
Tropicamide with associated blurred vision, though other dilated eyes were tracked without problem. 130 
3.2. Accuracy (concordance with HFA) 131 
Figure 2 shows individual data for 22 patients, including all 11 new referrals (Figure 2A), and 11 132 
randomly-selected follow-up patients with established diagnoses of glaucoma (Figure 2B). By 133 
inspection, it can be seen that Eyecatcher was often able to localize scotomas with reasonable spatial 134 
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precision. Note, for example, the nasal step in ID12, and the inferior temporal scotoma in ID22. In 135 
some cases, however, Eyecatcher did appear to underestimate (ID19) or mislocalise (ID17) the loss. 136 
As shown in Figure 3, there was good association (Spearman Correlation: r = 0.78; p < 0.001) between 137 
the overall summary measures from Eyecatcher (mean hit rate) and SAP (MD). Crucially, no individuals 138 
with substantial field loss were found to be visually normal by Eyecatcher (Figure 3, upper-left region), 139 
although some individuals with a healthy visual field did score poorly (Figure 3, bottom-right region). 140 
[ Figure 2 About Here ] 141 
 142 
 143 
Figure 2. Individual VF assessments for (A) all 11 new referrals (none of whom is believed to have glaucoma) and (B) 11 144 
randomly-selected follow-up patients (all with established diagnosis of glaucoma). In each case, the HFA greyscale is given 145 
on the left and the two corresponding Eyecatcher heatmaps on the right (Eyecatcher was performed twice). Red markers 146 
highlight regions of the HFA where loss was greater than the magnitude of Eyecatcher stimulus (– 6 dB). If concordance 147 
between the two tests was perfect, then red areas in the HFA should appear as red areas on the Eyecatcher heatmap. Note 148 
that new referral ID 9 was non-glaucomatous, but was a cataract patient with a generalized loss of sensitivity across the 149 
visual field (MD = -5.6 dB).  150 
[ Figure 3 About Here ] 151 
Figure 3. Agreement in overall sensitivity between Eyecatcher (Mean Hit-Rate) vs. SAP (HFA Mean Deviation; dB). Each 152 
data-point represents a single test/eye from a single patient. Each patient completed Eyecatcher twice, and the data from 153 
each run is given separately (circles, squares). The solid line shows the line of best fit (polynomial spline fit). Any data 154 
points falling in the top left shaded region would be considered a false-negative result (good performance on Eyecatcher, 155 
despite substantial field loss). 156 
3.3. Sensitivity and Specificity 157 
Eyecatcher demonstrated good separation between eyes with moderate or advanced field loss (< -6 158 
MD; N = 24) and those with a VF within normal limits (> -2 dB; N = 22), with an area under the receiver 159 
operating characteristic (AUROC) of 0.97 {CI95: 0.94, 0.99} (see Supplemental Figure S1). 160 
In terms of identifying unnecessary (‘false-positive’) new referrals to the clinic, we took a mean hit 161 
rate of 0.7 as an arbitrary cut off point for ‘good’ performance. Eight of 11 new referrals (all of whom 162 
were judged to be visually normal) scored above 0.7 (Sensitivity: 73%), while 0% of assessments from 163 
eyes with MD < -6 dB scored below 0.7 (Specificity: 100%). 164 
3.4. Test-retest Reliability 165 
Figure 4 shows Eyecatcher’s test-retest repeatability. The 95% Coefficient of Repeatability (CoR95) for 166 
Mean Hit Rate was 0.19 (19% of the test’s dynamic range. Note that Eyecatcher measures the % of 167 
fixed-intensity points seen, rather than luminance detection thresholds). For comparison, in SAP, the 168 
conventional summary metric MD has been shown previously27 to have a CoR95 of ~1.4 dB (~4% of 169 
range) at 0 dB MD, increasing to ~5.2 dB (~17% of range) at -30 dB MD. Thus, Eyecatcher was less 170 
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reliable (repeatable) than conventional SAP. There was no indication of systematic learning or fatigue 171 
across the two test runs. 172 
[ Figure 4 About Here ] 173 
Figure 4. Bland-Altman plot, showing test-retest repeatability for Eyecatcher (mean hit rate). Grey shaded regions show 95% confidence 174 
intervals for the mean. Dashed red lines indicate the 95% limits of agreement. 175 
3.5. Test Duration 176 
Median duration {CI95%} was 2.5 mins {2.4, 2.7} for Eyecatcher, and 3.5 {3.3, 4.1} mins for SAP (SITA 177 
Fast). This difference was significant (Pairwise t-test: P ≪ 0.001), though note that SAP tested more 178 
locations, and measured thresholds. Also note that these times do not include additional overheads, 179 
such as the time taken to seat/position the participant, explain the test, or apply refractive correction; 180 
all of which were minimal for Eyecatcher, but can be substantial for SAP. 181 
3.6. Usability 182 
Participants rated Eyecatcher more enjoyable, easier to perform, less tiring, and less hard to 183 
concentrate on than SAP (4 Pairwise t-tests: all P < 0.001). There was no difference in task-184 
comprehension (P = 0.419), which was near ceiling for both tests (see Supplemental Figure S2). There 185 
were no significant difference in patients’ perceptions of Eyecatcher between new referrals and 186 
follow-up patients (5 between-subject t-tests: all P > 0.05).  187 
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4. DISCUSSION  188 
This study considered the feasibility of using a portable, automated, eye-movement perimeter 189 
(Eyecatcher) to perform a rapid assay of VF loss in a real-world clinical setting. In particular, we 190 
examined whether it could be used as a preliminary ‘triage test’ for clinic waiting areas, to identify 191 
high-risk individuals (eyes with substantial VF loss: MD < -6 dB), and likely false-positive referrals (no 192 
visual field or optic nerve abnormalities). 193 
Eyecatcher demonstrated good separation (AUROC = 0.97) between eyes with moderate-to-advanced 194 
VF loss (< -6 dB MD) versus those within normal limits (> -2 dB MD). This is encouraging, as the vast 195 
majority of individuals expected to go blind within their lifetime already exhibit moderate or worse VF 196 
loss at presentation9. Eyecatcher might therefore be used to flag up these individuals as ‘high risk’. In 197 
terms of false-positive new referrals, 68% were correctly identified as having no substantial VF loss 198 
(MD > -6 dB), while crucially 0% of patients with established VF loss (MD < -6 dB) were incorrectly 199 
flagged as healthy. In practice, this might translate to two thirds of new referrals being granted an 200 
expedited discharge, while the remaining 1-in-3 patients would continue to wait to perform SAP as 201 
before. Taken together, the results suggest that Eyecatcher --- though still in early development --- 202 
exhibits potential promise as a way of prioritising patients, and filtering-out false-positive referrals, as 203 
called for by the HSIB (see Introduction). 204 
Crucially, Eyecatcher requires minimal clinical resources, being a fully automated, unsupervised 205 
procedure that does not require expensive, specialist equipment or a dedicated testing space (e.g., no 206 
precise control of lighting, with patients wearing their own glasses as available). Patients also 207 
exhibited no difficulties comprehending what to do, despite minimal instructions ("look at anything 208 
you see”). The present data would likely have been cleaner and more impressive if we had used 209 
‘research-grade’ protocols and equipment. However, such a test would be of little practical value as a 210 
real-world tool. As it was, it is possible to imagine rows of autonomous Eyecatcher-type devices 211 
installed in waiting rooms, or at the entrance to clinic – potentially using the same or similar hardware 212 
as current ‘self-service’ check-in system. 213 
Eyecatcher was fast (~2.5 mins, including eye-tracker calibration), but the HFA (SITA Fast) made 214 
detailed threshold measurements, at more locations, in only ~3.5 mins, and new HFA algorithms may 215 
be even faster than Eyecatcher28. The goal was not, however, to create a maximally fast test, but one 216 
that is easy, intuitive, and fast enough to run unsupervised. These 'human factors' were reflected in 217 
the fact that patients rated Eyecatcher easier and less tiring than traditional, button-press perimetry, 218 
and stands in stark contrast to SAP, where a technician must be continuously present to explain the 219 
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test and monitor performance, and where even well practiced patients can find the test challenging10 220 
or confusing. 221 
4.1. Limitations 222 
This study was intended only as an initial feasibility assessment. It should not be taken as a formal 223 
evaluation of diagnostic accuracy, which would require a standardized protocol29, and a much larger, 224 
multi-centre, prospective sample. A more comprehensive evaluation would also consider economic 225 
utility, and might examine test performance with different target intensities (fixed here at -6 dB). A 226 
smaller value might, for example, be beneficial if attempting to detect very early signs of glaucoma. 227 
Regarding Eyecatcher itself, the test is limited in three main ways. First, several patients (9%) could not 228 
complete the test due to the hardware being unable to track their eyes reliably. In five cases the 229 
difficulties were likely caused by recent ophthalmic interventions (e.g., cataract surgery). Such patients 230 
will be ‘in the system’ already and are not the sorts of ‘new referrals’ that a rapid triage test such as 231 
Eyecatcher would be primarily targeted at. In the other two cases, however, the cause of the problem 232 
was either unknown (N=1), or appeared to be due to a side effect of a common medication (dry eyes; 233 
N=1). These failures are concerning, but it is hoped that reliability of low-cost eye-tracking 234 
technologies will improve in time. In the meantime, such individuals could simply continue to perform 235 
SAP (as they do currently), or could perform a button-press version of Eyecatcher (see Supplemental 236 
Text). 237 
Second, since Eyecatcher requires an eye-movement response, it is unable to test central vision (e.g., 238 
the most central point was ±3° horizontal, ±6° vertical). This is unfortunate, since central vision is 239 
increasingly thought to be affected in early glaucoma30. More precise eye-tracking, or an alternative 240 
response measure, would be required if wanting to assess more central VF locations in future. 241 
Third, when it came to identifying false-positive referrals, Eyecatcher exhibited high specificity 242 
(identifying 100% of eyes with MD < -6 dB), but limited sensitivity (only 68% of false-positive referrals 243 
were correctly identified as having no measurable field loss). This asymmetry was by design. In triage, 244 
the cost of misidentifying a diseased eye as healthy (whereafter a new patient might be wrongly 245 
discharged) is far greater than the cost of misidentifying a healthy eye as diseased (whereafter the 246 
patient would simply continue to wait for a more detailed assessment). Eyecatcher therefore required 247 
multiple negative responses to register a location as ‘missed’, while a single positive response was 248 
sufficient to classify a location as ‘seen’ (see Supplemental Text). Sensitivity might be improved 249 
through improved test design or longer test durations. However, the practical corollary is that the 250 
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Eyecatcher, as it is currently, shows promise as a triage measure, but would make for a poor general 251 
screening device (i.e., where both high sensitivity and specificity are required). 252 
4.2. Further Possible Applications & Future Work 253 
Eyecatcher was intended as a rapid triage measure for use in clinics. Given its portability and ease of 254 
use, however, Eyecatcher might also be useful in situations that require testing outside of traditional 255 
eye clinics (e.g., home-monitoring, domiciliary services, or case-finding in developing rural 256 
communities), or for performing VF assessments in individuals with limited physical or cognitive 257 
abilities (e.g., infants or stroke patients). For people interested in adapting or developing Eyecatcher 258 
further, we have made all of the source code freely available online (see Methods). 259 
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